Kramer 1998.

Methods	Six‐week, randomised, double‐blind, placebo‐controlled study.
Participants	Out‐patients with a DSM‐IV diagnosis of major depression disorder (single or recurrent), a current episode of depression lasting at least 4 weeks (but less than 2 years) a score ≥22 (moderately depressed) on the Hamilton rating scale for depression (HDRS‐17), a score ≥15 (moderately high anxiety) on the Hamilton rating scale for anxiety (HAM‐A) and a score ≥4 (moderately ill) on the Clinical Global Impression (CGI) Severity. Patients considered at risk for suicide or violence were excluded.
Interventions	Paroxetine:72 participants. Aprepitant (MK‐869): 71 participants. Paroxetine dose: 20 mg/day. Aprepitant (MK‐869): 300 mg/day.
Outcomes	HDRS‐21, HAM‐A, CGI‐S.
Notes	Funding: aprepitant manufacturer.
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Quote: "randomized". No further details.
Allocation concealment (selection bias)	Unclear risk	No information provided.
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Quote: "double blind". No further details.
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Quote: "double blind". No further details.
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	More than 20% of participants in each arm abandoned the study prematurely.
Selective reporting (reporting bias)	High risk	Outcomes data not clearly reported. Only side effects with an incidence of > or = 5% were reported.
Other bias	Unclear risk	Sponsorship bias cannot be ruled out.